Full year 2020 revenue of $71.1m compared to full year 2019 revenue of $72.6m, reflecting the impact of COVID-19 on elective surgeries
Guidance for full year 2021 sales growth in the range of 31-38%, reaching $93-98 million
WARSAW, Ind., March 10, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") KIDS, a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2020.
Fourth Quarter / Full Year 2020 and Business Highlights
- Generated total revenue of $18.9 million for the fourth quarter, down 0.1% from $19.0 million in fourth quarter 2019.
- Full year 2020 revenue decreased 2.0% to $71.1 million from full year 2019 revenue due to the impact of COVID-19 on elective surgery volumes.
- Recorded a $2.7 million revenue reduction due to the repurchase of inventory from a stocking distributor in Germany, Austria, and Switzerland that we converted to a sales agency in December 2020.
- The $2.7 million reduction impacted fourth quarter revenue growth by (14%) and total year revenue growth by (4%).
- Domestic revenue growth in the fourth quarter of 26.1% compared to prior year with particular strength in Scoliosis and Sports Medicine/Other.
- Continued acceleration of international sales agency revenue growth of 51% in the fourth quarter, up from 26% in the third quarter of 2020.
- Delivered strong synergies from acquisitions with 38 Orthex surgeon conversions, ApiFix receiving full approvals at 11 of the 20 IRB hospitals, and successful completion of 20 ApiFix surgeries through end of December 2020.
- Strengthened liquidity position with $70.2 million in net proceeds from follow-on public offering in June 2020.
Mark Throdahl, Chief Executive Officer of OrthoPediatrics, commented, "Despite COVID-19, in 2020 we continued the systematic execution of our growth initiatives both domestically and internationally. Elective surgery volumes declined globally but staged a gradual recovery throughout the year. Second quarter sales declined 25% but then began to recover with third quarter sales growth of 7% and a 0.1% fourth quarter sales decline due to the $2.7 million reduction which impacted fourth quarter revenue growth by (14%). During the fourth quarter, our domestic business grew 26% and international agencies grew 51%, supporting the beginning of an international sales turnaround. We are optimistic about the outlook in 2021, particularly with the resumption of strong international growth. As we look ahead, we will continue to execute on our growth plans to support full year 2021 revenue guidance of 31-38%. We believe we will see strong contributions from new domestic Orthex users, continued acceleration of conversions, and the Orthex European launch in the second quarter of 2021. Furthermore, Apifix will complete its 200-case registry by late 2021, and the deployment of $18 million of consigned sets in 2019 and 2020 will positively impact domestic and international sales agency markets."
Mr. Throdahl continued, "We would like to recognize the commitment and discipline of our associates around the world who rose to the challenge of 2020. We would also like to thank our shareholders for their continued support during an unprecedented year. Last week we reached the milestone of an estimated 200,000 surgeries since the Company was founded. We remain dedicated to helping children throughout the world and driving increased value for our stakeholders in 2021 and beyond."
Fourth Quarter and Full Year 2020 Financial Results
Total revenue for the fourth quarter of 2020 was $18.9 million, a 0.1% decrease compared to $19.0 million for the same period last year. U.S. revenue for the fourth quarter of 2020 was $17.9 million, a 26.1% increase compared to $14.2 million for the same period last year, representing 94.3% of total revenue. International revenue for the fourth quarter of 2020 was $1.1 million, a 77.7% decrease compared to $4.8 million for the same period last year, representing 5.7% of total revenue. In December 2020, we recorded a $2.7 million reduction of revenue due to the repurchase of inventory related to the conversion of a stocking distributor in Germany, Austria, and Switzerland to a sales agency.
Total revenue for 2020 was $71.1 million, a 2% decrease compared to $72.6 million for 2019. Our U.S. revenue for 2020 was $63.0 million, a 14.4% increase compared to $55.1 million for 2019, representing 88.6% of total revenue. Our international revenue for 2020 was $8.1 million, a 53.6% decrease compared to $17.5 million for 2019, representing 11.4% of total revenue due to inclusion of the aforementioned $2.7 million reduction of revenue.
Trauma and Deformity revenue for the fourth quarter of 2020 was $11.3 million, a 17.3% decrease compared to $13.6 million for the same period last year due to the aforementioned $2.7 million reduction of revenue. Scoliosis revenue was $6.6 million, a 35.7% increase compared to $4.9 million for the fourth quarter of 2019. Sports Medicine/other revenue for the fourth quarter of 2020 was $1.0 million, a 134.9% increase compared to $430 thousand for the same period last year.
Trauma and Deformity revenue for 2020 was $47.7 million, a 3.4% decrease compared to $49.4 million for 2019, reflecting the aforementioned $2.7 million reduction of revenue. Scoliosis revenue for 2020 was $20.7 million, a 3.5% decrease compared to $21.5 million for 2019. Sports medicine/other revenue for 2020 was $2.7 million, a 57.0% increase compared to $1.7 million in 2019.
Gross profit for the fourth quarter of 2020 was $15.1 million, a 4.6% increase compared to $14.5 million for the same period last year, and $55.0 million for 2020, a 0.8% increase compared to $54.6 million for 2019. Gross profit margin for the fourth quarter of 2020 improved to 79.9%, compared to 76.2% for the same period last year, and was 77.4% for 2020, compared to 75.3% for 2019. The aforementioned $2.7 million reduction of revenue reduced gross profit in the fourth quarter and total year of 2020 by $1.1 million.
Total operating expenses for the fourth quarter of 2020 were $27.9 million, a 59.4% increase compared to $17.5 million for the same period last year. The primary increase during the fourth quarter was due to accrued legal settlements of $6.3 million. Full year operating expenses were $81.8 million for 2020, a 28.4% increase compared to $63.7 million for 2019. The increase in operating expenses for full year 2020 was primarily driven by a 43.7% increase in general and administrative driven by accrued legal settlements of $6.3 million and addition of personnel and resources to support the expansion of our business. Operating loss for 2020 was ($26.8) million compared to ($9.1) million for 2019.
Net interest expense for the fourth quarter of 2020 was $0.6 million, compared to $1.3 million for the same period last year, and was $3.4 million for 2020 compared to $3.5 million for 2019. Fair value adjustment of contingent consideration was $1.7 million for the fourth quarter of 2020 and $3.5 million for the full year 2020, compared to zero for both periods in 2019.
Net loss from continuing operations for the fourth quarter of 2020 was ($14.0) million, compared to ($4.3) million for the same period last year. Total net loss including discontinued operations for the fourth quarter of 2020 was ($14.0) million, or ($0.73) per basic diluted share attributable to common stockholders, compared to ($5.4) million, or ($0.36) per basic and diluted share for the same period last year. Adjusted EBITDA for the fourth quarter of 2020 and 2019 was ($2.6) million and ($0.9) million, respectively.
Net loss from continuing operations for 2020 was ($32.9) million, compared to ($12.7) million for 2019. Total net loss including discontinued operations for the full year 2020 was ($32.9) million, or ($1.82) per basic and diluted share attributable to common stockholders, compared to ($13.7) million, or ($0.94) per basic and diluted share for 2019. Adjusted EBITDA for the full year 2020 was ($5.9) million, compared to ($1.1) million for the full year 2019. See below for additional information and a reconciliation of non-GAAP financial information.
The weighted average number of diluted shares outstanding for the three-month period ended December 31, 2020 was 19,118,276 shares.
In the fourth quarter of 2020, we had 171 sales representatives up 2.4% compared to 167 in the same period of 2019.
The change in property and equipment during the fourth quarter of 2020 was $4.1 million, which compared to an increase of $1.3 million for the same period last year, and $10.5 million for 2020, compared to $11.8 million for 2019. This investment reflects the deployment of consigned sets, which includes product specific instruments and cases and trays. Including the implants, $5.0 million of consigned sets were deployed during the fourth quarter of 2020, compared to $4.5 million during the fourth quarter of 2019.
As of December 31, 2020, cash, cash equivalents, short-term investments and restricted cash were $85.3 million, compared to $89.7 million as of September 30, 2020. The Company, together with all unpaid interest and other related amounts payable, has no outstanding term loan obligations.
Full Year 2021 Financial Guidance
For full year 2021, we expect to see very significant growth over full year 2020 with sales reaching $93-98 million, representing a range of 31%-38% growth. We expect domestic growth to continue, approaching pre-COVID levels and expect significant improvement in international sales due to the recovery by stocking distributors and continued sales agency growth, starting in the first quarter of 2021.
Conference Call
OrthoPediatrics will host a conference call on Thursday, March 11, 2021, at 8:00 a.m. ET to discuss the results. The dial-in numbers are (855) 289-4603 for domestic callers and (614) 999-9389 for international callers. The conference ID number is 9362699. A live webcast of the conference call will be available online from the investor relations page of the OrthoPediatrics' corporate website at www.orthopediatrics.com.
A replay of the webcast will remain available on OrthoPediatrics' website, www.orthopediatrics.com, until the Company releases its first quarter 2021 financial results. In addition, a telephonic replay of the call will be available until March 18, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 9362699.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential," "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics' control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others: the risks related to COVID-19, the impact such pandemic may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 5, 2020, as updated and supplemented by our other SEC reports filed from time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Adjusted EBITDA in this release represents net loss from continuing operations, plus interest expense, net plus other expense, provision for income taxes (benefit), depreciation and amortization, stock-based compensation expense, fair value adjustment of contingent consideration, acquisition related costs and accrued legal settlements costs. Adjusted EBITDA is presented because the Company believes it is a useful indicator of its operating performance. Management uses the metric as a measure of the Company's operating performance and for planning purposes, including financial projections. The Company believes this measure is useful to investors as supplemental information because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company's presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using Adjusted EBITDA on a supplemental basis. The Company's definition of this measure is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain a reconciliation of Net Loss from continuing operations to non-GAAP Adjusted EBITDA.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 44 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
The Ruth Group
Christine Petraglia
SVP Investor Relations
(917) 633-8980
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In Thousands, Except Share Data)
| December 31, | December 31, | |||||||
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,758 | $ | 70,777 | ||||
| Restricted cash | 1,374 | 1,250 | ||||||
| Short term marketable securities | 55,141 | - | ||||||
| Accounts receivable - trade, less allowance for doubtful accounts of $433 and $506, respectively | 17,212 | 16,003 | ||||||
| Inventories, net | 52,989 | 38,000 | ||||||
| Notes Receivable | 337 | 564 | ||||||
| Prepaid expenses and other current assets | 2,618 | 1,464 | ||||||
| Total current assets | 158,429 | 128,058 | ||||||
| Property and equipment, net | 27,227 | 21,349 | ||||||
| Other assets: | ||||||||
| Amortizable intangible assets, net | 50,284 | 14,484 | ||||||
| Goodwill | 70,511 | 13,773 | ||||||
| Other intangible assets | 13,961 | 4,490 | ||||||
| Total other assets | 134,756 | 32,747 | ||||||
| Total assets | $ | 320,412 | $ | 182,154 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable - trade | $ | 10,038 | $ | 6,467 | ||||
| Accrued compensation and benefits | 4,540 | 4,349 | ||||||
| Accrued legal settlements | 6,342 | - | ||||||
| Current portion of long-term debt with affiliate | 131 | 124 | ||||||
| Current portion of acquisition installment payable | 12,233 | - | ||||||
| Other current liabilities | 1,744 | 2,723 | ||||||
| Total current liabilities | 35,028 | 13,663 | ||||||
| Long-term liabilities: | ||||||||
| Long-term debt with affiliate, net of current portion | 1,044 | 26,067 | ||||||
| Acquisition installment payable, net of current portion | 12,784 | - | ||||||
| Contingent consideration | 30,710 | - | ||||||
| Deferred income taxes | 5,755 | - | ||||||
| Operating lease liabilities, net of current portion | 323 | 63 | ||||||
| Total long-term liabilities | 50,616 | 26,130 | ||||||
| Total liabilities | 85,644 | 39,793 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Common stock, $0.00025 par value; 50,000,000 shares authorized; 19,560,291 shares and 16,723,128 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively | 5 | 4 | ||||||
| Additional paid-in capital | 388,622 | 271,182 | ||||||
| Accumulated deficit | (161,766 | ) | (128,822 | ) | ||||
| Accumulated other comprehensive income (loss) | 7,907 | (3 | ) | |||||
| Total stockholders' equity | 234,768 | 142,361 | ||||||
| Total liabilities and stockholders' equity | $ | 320,412 | $ | 182,154 | ||||
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Net revenue | $ | 18,924 | $ | 18,952 | $ | 71,078 | $ | 72,552 | |||||||
| Cost of revenue | 3,806 | 4,502 | 16,047 | 17,933 | |||||||||||
| Gross profit | 15,118 | 14,450 | 55,031 | 54,619 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 9,433 | 8,360 | 31,854 | 31,284 | |||||||||||
| General and administrative | 10,036 | 7,216 | 38,317 | 26,664 | |||||||||||
| Legal settlement expenses | 6,342 | - | 6,342 | - | |||||||||||
| Research and development | 2,050 | 1,905 | 5,273 | 5,748 | |||||||||||
| Total operating expenses | 27,861 | 17,481 | 81,786 | 63,696 | |||||||||||
| Operating loss | (12,743 | ) | (3,031 | ) | (26,755 | ) | (9,077 | ) | |||||||
| Other expenses: | |||||||||||||||
| Interest expense, net | 624 | 1,306 | 3,412 | 3,538 | |||||||||||
| Fair value adjustment of contingent consideration | 1,701 | - | 3,520 | - | |||||||||||
| Other expense (income) | (332 | ) | (8 | ) | (20 | ) | 70 | ||||||||
| Total other expenses | 1,993 | 1,298 | 6,912 | 3,608 | |||||||||||
| Loss before income taxes | (14,736 | ) | (4,329 | ) | (33,667 | ) | (12,685 | ) | |||||||
| Provision for income taxes (benefit) | (723 | ) | - | (723 | ) | - | |||||||||
| Net loss from continuing operations | (14,013 | ) | (4,329 | ) | (32,944 | ) | (12,685 | ) | |||||||
| Net loss from discontinued operations | - | 1,100 | - | 1,046 | |||||||||||
| Net loss | $ | (14,013 | ) | $ | (5,429 | ) | $ | (32,944 | ) | $ | (13,731 | ) | |||
| Weighted average common shares - basic and diluted | 19,118,276 | 15,031,256 | 18,056,828 | 14,624,194 | |||||||||||
| Net loss from continuing operations per share attributable to common stockholders - basic and diluted | $ | (0.73 | ) | $ | (0.29 | ) | $ | (1.82 | ) | $ | (0.87 | ) | |||
| Net loss from discontinued operations per share attributable to common stockholders - basic and diluted | $ | - | $ | (0.07 | ) | $ | - | $ | (0.07 | ) | |||||
| Net loss per share attributable to common stockholders - basic and diluted | $ | (0.73 | ) | $ | (0.36 | ) | $ | (1.82 | ) | $ | (0.94 | ) | |||
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)
| For the Twelve Months Ended December 31, | |||||||
| 2020 | 2019 | ||||||
| OPERATING ACTIVITIES | |||||||
| Net loss | $ | (32,944 | ) | $ | (13,731 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Loss on sale of assets held for sale | - | 210 | |||||
| Depreciation and amortization | 8,010 | 4,671 | |||||
| Stock-based compensation | 6,196 | 2,603 | |||||
| Fair value adjustment of contingent consideration | 3,520 | - | |||||
| Acquisition installment payable | 2,397 | - | |||||
| Deferred income taxes | (723 | ) | - | ||||
| Changes in certain current assets and liabilities: | |||||||
| Accounts receivable - trade | (451 | ) | (5,820 | ) | |||
| Inventories | (12,070 | ) | (9,767 | ) | |||
| Prepaid expenses and other current assets | (719 | ) | (137 | ) | |||
| Accounts payable - trade | 3,071 | 2,401 | |||||
| Accrued legal settlements | 6,342 | - | |||||
| Accrued expenses and other liabilities | (1,074 | ) | 1,946 | ||||
| Other | (85 | ) | (1 | ) | |||
| Net cash used in operating activities - continuing operations | (18,530 | ) | (17,625 | ) | |||
| Net cash provided by operating activities - discontinued operations | - | (144 | ) | ||||
| Net cash used in operating activities | (18,530 | ) | (17,769 | ) | |||
| INVESTING ACTIVITIES | |||||||
| Acquisition of Telos, net of cash acquired | (1,670 | ) | - | ||||
| Acquisition of ApiFix, net of cash acquired | (1,723 | ) | - | ||||
| Acquisition of Band-Lok intangible assets | (796 | ) | - | ||||
| Acquisition of Vilex and Orthex, net of cash acquired | - | (49,836 | ) | ||||
| Purchases of licenses | - | (270 | ) | ||||
| Purchase of short term investments | (55,000 | ) | - | ||||
| Purchases of property and equipment | (10,504 | ) | (11,816 | ) | |||
| Net cash used in investing activities | (69,693 | ) | (61,922 | ) | |||
| FINANCING ACTIVITIES | |||||||
| Payments on note with affiliate | (25,000 | ) | - | ||||
| Proceeds from issuance of debt with affiliate | - | 30,000 | |||||
| Proceeds from issuance of common stock, net of issuance costs | 70,207 | 59,996 | |||||
| Proceeds from exercise of stock options | 1,650 | 1,141 | |||||
| Payments on mortgage notes | (125 | ) | (118 | ) | |||
| Net cash provided by financing activities | 46,732 | 91,019 | |||||
| Effect of exchange rate changes on cash | (404 | ) | 8 | ||||
| NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH | (41,895 | ) | 11,336 | ||||
| Cash and restricted cash, beginning of period | $ | 72,027 | $ | 60,691 | |||
| Cash and restricted cash, end of period | $ | 30,132 | $ | 72,027 | |||
| SUPPLEMENTAL DISCLOSURES | |||||||
| Cash paid for interest | $ | 1,233 | $ | 4,229 | |||
| Transfer of instruments from property and equipment to inventory | $ | 415 | $ | 1,037 | |||
| Issuance of common shares to acquire Vilex and Orthex | $ | - | $ | 10,000 | |||
| Issuance of common shares to acquire Telos | $ | 1,568 | $ | - | |||
| Issuance of common shares to acquire ApiFix | $ | 35,176 | $ | - | |||
| Issuance of common shares to acquire Band-Lok intellectual property | $ | 2,644 | $ | - | |||
| Divestiture consideration allocated to assets held for sale | $ | - | $ | 25,000 | |||
| Payment of Term Note B with revolving credit facility | $ | - | $ | 5,000 | |||
ORTHOPEDIATRICS CORP.
NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY
(Unaudited)
(In Thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| Product sales by geographic location: | 2020 | 2019 | 2020 | 2019 | |||||||
| U.S. | $ | 17,853 | $ | 14,155 | $ | 62,966 | $ | 55,055 | |||
| International | 1,071 | 4,797 | 8,112 | 17,497 | |||||||
| Total | $ | 18,924 | $ | 18,952 | $ | 71,078 | $ | 72,552 | |||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| Product sales by category: | 2020 | 2019 | 2020 | 2019 | |||||||
| Trauma and deformity | $ | 11,278 | $ | 13,631 | $ | 47,677 | $ | 49,371 | |||
| Scoliosis | 6,636 | 4,891 | 20,738 | 21,485 | |||||||
| Sports medicine/other | 1,010 | 430 | 2,663 | 1,696 | |||||||
| Total | $ | 18,924 | $ | 18,952 | $ | 71,078 | $ | 72,552 | |||
ORTHOPEDIATRICS CORP.
RECONCILIATION OF NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
(In Thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||
| Net loss from continuing operations | (14,013 | ) | (4,329 | ) | (32,944 | ) | (12,685 | ) | |||||
| Interest expense, net | 624 | 1,306 | 3,412 | 3,538 | |||||||||
| Other expense | (332 | ) | (8 | ) | (20 | ) | 70 | ||||||
| Provision for income taxes (benefit) | (723 | ) | - | (723 | ) | - | |||||||
| Depreciation and amortization | 2,314 | 1,405 | 8,010 | 4,671 | |||||||||
| Stock-based compensation | 1,484 | 707 | 6,196 | 2,603 | |||||||||
| Fair value adjustment of contingent consideration | 1,701 | - | 3,520 | - | |||||||||
| Acquisition related costs | - | - | 336 | 737 | |||||||||
| Accrued legal settlement costs | 6,342 | - | 6,342 | - | |||||||||
| Adjusted EBITDA | $ | (2,603 | ) | $ | (919 | ) | $ | (5,871 | ) | $ | (1,066 | ) | |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
